Published in Endocr Pathol on January 01, 2000
Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa. World J Gastroenterol (2005) 0.98
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer (2006) 0.93
Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma. PLoS One (2014) 0.78
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A (1999) 3.43
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol (1997) 2.76
The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst (1998) 2.53
The VHL tumour-suppressor gene paradigm. Trends Genet (1998) 1.94
Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res (1996) 1.81
A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci U S A (1998) 1.77
pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A (1998) 1.74
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res (1998) 1.71
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol (1996) 1.64
von Hippel-Lindau gene mutations in N-nitrosodimethylamine-induced rat renal epithelial tumors. J Natl Cancer Inst (1998) 1.48
Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res (1998) 1.46
Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene (1995) 1.44
Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol (1986) 1.35
Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest (1996) 1.25
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res (1998) 1.20
Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab (1997) 1.17
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol (1997) 1.09
An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet (1998) 1.07
Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol (1998) 1.06
The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem (1997) 1.02
Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol (1997) 1.01
Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab (1997) 1.01
Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene (1994) 0.98
Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. Int J Cancer (1998) 0.95
The molecular basis of von Hippel-Lindau disease. Mol Med (1997) 0.95
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res (1999) 0.94
Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med (1998) 0.88
Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol (1995) 0.85
Prognostic factors in thyroid carcinomas. Verh Dtsch Ges Pathol (1997) 0.85
Loss of heterozygosity of the von Hippel Lindau gene locus in polypoid dysplasia but not flat dysplasia in ulcerative colitis or sporadic adenomas. Hum Pathol (1998) 0.83
Expression of von Hippel-Lindau protein in normal and pathological human tissues. Histochem J (1999) 0.83
Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res (1997) 0.82
Oncogenes and antioncogenes involved in human thyroid carcinogenesis. J Exp Clin Cancer Res (1997) 0.76
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med (2003) 3.94
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope (2011) 2.55
Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol (2010) 2.49
The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery (2003) 2.38
Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg (2012) 2.38
Latencies shorter than 3.5 ms after vagus nerve stimulation signify a nonrecurrent inferior laryngeal nerve before dissection. Ann Surg (2011) 2.22
Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg (2001) 1.89
Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res (2003) 1.83
Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate (2006) 1.74
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol (2006) 1.71
Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg (2004) 1.70
Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet (2002) 1.69
Disparities between male and female patients with thyroid cancers: sex difference or gender divide? Clin Endocrinol (Oxf) (2006) 1.67
Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol (2004) 1.60
Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab (2006) 1.55
The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer (2005) 1.54
Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab (2007) 1.51
Melatonin and type 2 diabetes - a possible link? J Pineal Res (2007) 1.50
Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab (2005) 1.50
Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery (2003) 1.46
Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int (2010) 1.44
Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology (2009) 1.41
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol (2006) 1.40
External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope (2013) 1.40
Association of HLA DQ4-DR8 haplotype with papillary thyroid carcinomas. Clin Endocrinol (Oxf) (2006) 1.39
Expression of Ki-67 in squamous cell carcinoma of the penis. BJU Int (2005) 1.39
Significance of marginally elevated calcitonin levels in micromedullary thyroid cancer. Ann Surg Oncol (2009) 1.38
Skeletal muscle metastases: primary tumours, prevalence, and radiological features. Eur Radiol (2009) 1.38
Quantitative multi-gene expression profiling of primary prostate cancer. Prostate (2006) 1.36
Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia (2008) 1.32
Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One (2012) 1.30
5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms. J Pharmacol Exp Ther (2004) 1.27
Value of a protective stoma in low anterior resections for rectal cancer. Dis Colon Rectum (2002) 1.24
25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab (2002) 1.24
Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res (2005) 1.22
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab (2012) 1.21
Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer (2004) 1.17
Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg (2004) 1.16
Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther (2004) 1.16
Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab (2005) 1.16
Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene (2003) 1.15
Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res (2002) 1.15
Intraoperative neuromonitoring of surgery for benign goiter. Am J Surg (2002) 1.13
CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol (2004) 1.13
Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: An exploratory analysis. Surgery (2008) 1.12
Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury. Head Neck (2012) 1.12
Prospero-related homeobox 1 (PROX1) is frequently inactivated by genomic deletions and epigenetic silencing in carcinomas of the bilary system. J Hepatol (2006) 1.12
Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clin Endocrinol (Oxf) (2008) 1.12
Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab (2010) 1.11
Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res (2003) 1.11
Primary breast sarcoma: prevalence, clinical signs, and radiological features. Acta Radiol (2011) 1.11
Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer (2005) 1.10
Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res (2003) 1.10
Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol (2002) 1.09
KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol (2003) 1.08
Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery (2008) 1.08
Breast plasmacytoma. Acta Radiol (2010) 1.08
Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer (2009) 1.07
Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch (2001) 1.06
The Treatment of Well-Differentiated Thyroid Carcinoma. Dtsch Arztebl Int (2015) 1.06
Validity of intra-operative neuromonitoring signals in thyroid surgery. Langenbecks Arch Surg (2004) 1.05
Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) (2007) 1.04
RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome? Surgery (2002) 1.04
CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid (2006) 1.04
Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg (2007) 1.03
High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol (2003) 1.03
siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol (2004) 1.03
Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys (2006) 1.03
Evidence for a role of the amyloid precursor protein in thyroid carcinogenesis. J Endocrinol (2008) 1.03
Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features. Acad Radiol (2011) 1.02
Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol (2003) 1.02
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol (2006) 1.02
German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg (2011) 1.02
Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol (2004) 1.02
Gains of 13q are correlated with a poor prognosis in liposarcoma. Mod Pathol (2005) 1.01
Factors influencing the agreement on histopathological assessments of breast biopsies among pathologists. Histopathology (2011) 1.01
Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol (2003) 1.01
Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg (2007) 1.00
Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg (2007) 1.00
Continuous vagal IONM prevents recurrent laryngeal nerve paralysis by revealing initial EMG changes of impending neuropraxic injury: a prospective, multicenter study. Laryngoscope (2014) 0.99
Correlation between the number of lymph node metastases and lung metastasis in papillary thyroid cancer. J Clin Endocrinol Metab (2012) 0.99
Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf) (2008) 0.99
Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg (2009) 0.99
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer (2009) 0.99
Intra-operative quick insulin assay to confirm complete resection of insulinomas guided by selective arterial calcium injection (SACI). Langenbecks Arch Surg (2007) 0.98
Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol (2003) 0.98
Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer (2002) 0.98
Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene (2005) 0.98
Identification of the non-recurrent inferior laryngeal nerve using intraoperative neurostimulation. Langenbecks Arch Surg (2001) 0.98
Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression. Cancer (2005) 0.96
Magnetic resonance imaging of intramuscular metastases. Skeletal Radiol (2010) 0.95